Participate in Research

Clinical Trial for People Diagnosed with Myasthenia Gravis
Protocol: STUDY00007113
Full Title
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)
The University at Buffalo (UB) Department of Neurology is conducting a study for people diagnosed with myasthenia gravis (MG). MG is a rare condition that causes muscle weakness of the eyes, face, and limbs and eye problems such as drooping or double vision. People with MG might also experience problems with speaking, swallowing, and chewing. The goal of the study is to see if a new drug (batoclimab) can help to improve the symptoms of MG.

Participants will be enrolled in this study for 84 weeks. They will attend up to 34 study visits and will receive weekly injections of either the study drug or a placebo (which looks like the study drug but does not contain any active medication). They will also have neurology exams and blood draws throughout the study.
Compensation: No
Adults 18 years or older Have been diagnosed with myasthenia gravis (MG)
Age Group: Adults
Principal Investigator: NICHOLAS SILVESTRI Open Study
+1 716-829-5037
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions